Physician

KT103-16 and KT103-96 - vanA/B EVIGENE

Available in the EU for in vitro diagnostic use (CE-IVD).
 

vanA/B EVIGENE provides rapid and accurate detection of the vanA/vanB genes from positive blood cultures and isolates of enterococci and S. aureus.

Available in 16 or 96 tests formats.

Features and Benefits

vanA/B EVIGENE, 16 tests (Cat. No. KT103-16) *New* 
vanA/B EVIGENE, 96 tests (Cat. No. KT103-96)  

 VRE – Vancomycin-Resistant Enterococci
Enterococci are bacteria normally present in the human intestine and are spread via direct contact with stool, urine, or blood.  Virtually unknown in the United States until the early 1990s, VRE now represents a leading cause of hospital-acquired infections, with over 30% of all enterococci infections in hospital intensive care units due to VRE; likely a result of increased vancomycin usage.(1,2)

While several genes, including vanA, vanB, vanC, vanD, and vanE, contribute to resistance to vancomycin in enterococci, vanA and vanB are considered to be associated with clinical manifestations of VRE.  The vanA gene has even been detected in isolates of vancomycin-resistant S. aureus (VRSA), further stressing the need for rapid and accurate methods for detecting the genetic markers in bacteria.(2,3)

1 NNIS System.  http://www.cdc.gov/ncidod/dhqp/pdf/ar/ICU_RESTrend1995-2004.pdf

2 Arthur M, Reynolds P, Courvalin P.  Glycopeptide resistance in enterococci. Trends Microbiol 1996;4:401-7

3 MMWR  Report, July 5, 2002 / 51(26);565-567. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5126a1.htm